Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined wit… Read more
Puma Biotechnology Inc - Asset Resilience Ratio
Puma Biotechnology Inc (PBYI) has an Asset Resilience Ratio of 31.39% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Puma Biotechnology Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Puma Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $67.90 Million | 31.39% |
| Total Liquid Assets | $67.90 Million | 31.39% |
Asset Resilience Insights
- Very High Liquidity: Puma Biotechnology Inc maintains exceptional liquid asset reserves at 31.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Puma Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Puma Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Puma Biotechnology Inc (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Puma Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.39% | $67.89 Million | $216.30 Million | +16.51pp |
| 2024-12-31 | 14.88% | $31.75 Million | $213.33 Million | +9.96pp |
| 2023-12-31 | 4.93% | $11.35 Million | $230.53 Million | +2.73pp |
| 2022-12-31 | 2.19% | $4.87 Million | $222.06 Million | -6.18pp |
| 2021-12-31 | 8.37% | $18.98 Million | $226.59 Million | +5.06pp |
| 2020-12-31 | 3.32% | $8.10 Million | $244.22 Million | -18.65pp |
| 2019-12-31 | 21.97% | $51.61 Million | $234.91 Million | -0.03pp |
| 2018-12-31 | 22.00% | $57.00 Million | $259.12 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $165.53 Million | -- |
| 2016-12-31 | 13.85% | $35.00 Million | $252.79 Million | -63.00pp |
| 2015-12-31 | 76.84% | $184.30 Million | $239.84 Million | +13.68pp |
| 2014-12-31 | 63.16% | $102.80 Million | $162.76 Million | +23.97pp |
| 2013-12-31 | 39.19% | $40.90 Million | $104.37 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $151.70 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $55.40 Million | -- |